Complex Interaction Between Visceral Adiposity and Metabolic Dysfunction-Associated Steatotic Liver Disease.
作者信息
Wong Vincent Wai-Sun
机构信息
Medical Data Analytics Center, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.
State Key Laboratory of Digestive Disease, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China.
出版信息
J Clin Exp Hepatol. 2025 Jan-Feb;15(1):102426. doi: 10.1016/j.jceh.2024.102426. Epub 2024 Oct 15.
Abstract
摘要
相似文献
1
Complex Interaction Between Visceral Adiposity and Metabolic Dysfunction-Associated Steatotic Liver Disease.内脏脂肪与代谢功能障碍相关脂肪性肝病之间的复杂相互作用
J Clin Exp Hepatol. 2025 Jan-Feb;15(1):102426. doi: 10.1016/j.jceh.2024.102426. Epub 2024 Oct 15.
2
Visceral Fat and Diabetes: Associations With Liver Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease.内脏脂肪与糖尿病：在代谢功能障碍相关脂肪性肝病中与肝纤维化的关联
J Clin Exp Hepatol. 2025 Jan-Feb;15(1):102378. doi: 10.1016/j.jceh.2024.102378. Epub 2024 Jul 19.
3
Epicardial and liver fat implications in albuminuria: a retrospective study.心外膜和肝脂肪对白蛋白尿的影响：一项回顾性研究。
Cardiovasc Diabetol. 2024 Aug 22;23(1):308. doi: 10.1186/s12933-024-02399-5.
4
Serial changes in metabolic dysfunction-associated steatotic liver disease after sleeve gastrectomy and their associations with abdominal adiposity: a prospective cohort study.袖状胃切除术后代谢功能障碍相关脂肪性肝病的系列变化及其与腹部肥胖的关联：一项前瞻性队列研究
Surg Obes Relat Dis. 2025 May;21(5):537-546. doi: 10.1016/j.soard.2024.11.007. Epub 2024 Nov 29.
5
The association between inflammatory, metabolic, and hepatic fibrosis-related biomarkers and atrial fibrillation in older patients with metabolic dysfunction-associated steatotic liver disease.炎症、代谢及肝纤维化相关生物标志物与老年代谢功能障碍相关脂肪性肝病患者心房颤动之间的关联。
BMC Geriatr. 2025 Jul 2;25(1):459. doi: 10.1186/s12877-025-06120-3.
6
Association between dietary flavonoids intake and metabolic dysfunction-associated steatotic liver disease especially in non-smokers: a cross-sectional study in US adults.膳食类黄酮摄入量与代谢功能障碍相关脂肪性肝病之间的关联，尤其是在非吸烟者中：一项针对美国成年人的横断面研究
BMC Gastroenterol. 2025 Jul 1;25(1):479. doi: 10.1186/s12876-025-04060-1.
7
Comparison of Non-invasive Liver Fat Scoring Systems as Markers of Metabolic Dysfunction-Associated Liver Disease.作为代谢功能障碍相关肝病标志物的非侵入性肝脂肪评分系统比较
Cureus. 2024 Oct 23;16(10):e72222. doi: 10.7759/cureus.72222. eCollection 2024 Oct.
8
Visceral adiposity index as a predictor of metabolic dysfunction-associated steatotic liver disease: a cross-sectional study.内脏脂肪指数作为代谢功能障碍相关脂肪性肝病的预测指标：一项横断面研究。
BMC Gastroenterol. 2025 May 1;25(1):326. doi: 10.1186/s12876-025-03957-1.
9
Prevalence, severity and determinants of steatotic liver disease among individuals with metabolic and alcohol risk from the community.社区中具有代谢和酒精风险个体的脂肪性肝病患病率、严重程度及决定因素
J Hepatol. 2025 Jul 4. doi: 10.1016/j.jhep.2025.06.020.
10
Hyperuricemia-Especially "Metabolic Hyperuricemia"-Is Independently Associated with a Higher Risk of Steatotic Liver Disease.高尿酸血症——尤其是“代谢性高尿酸血症”——与脂肪性肝病的较高风险独立相关。
Metabolites. 2025 May 28;15(6):356. doi: 10.3390/metabo15060356.
引用本文的文献
1
Comment on "Outcomes of Acute Pancreatitis in Lean Versus Non-lean Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Patients: A Nationwide Analysis".关于“瘦型与非瘦型代谢功能障碍相关脂肪性肝病（MASLD）患者急性胰腺炎的结局：一项全国性分析”的评论
Dig Dis Sci. 2025 Aug 20. doi: 10.1007/s10620-025-09340-0.
本文引用的文献
1
Central Obesity is an Independent Determinant of Advanced Fibrosis in Lean Patients With Nonalcoholic Fatty Liver Disease.中心性肥胖是非酒精性脂肪性肝病瘦患者发生高级纤维化的独立决定因素。
J Clin Exp Hepatol. 2025 Jan-Feb;15(1):102400. doi: 10.1016/j.jceh.2024.102400. Epub 2024 Aug 10.
2
Visceral Fat and Diabetes: Associations With Liver Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease.内脏脂肪与糖尿病：在代谢功能障碍相关脂肪性肝病中与肝纤维化的关联
J Clin Exp Hepatol. 2025 Jan-Feb;15(1):102378. doi: 10.1016/j.jceh.2024.102378. Epub 2024 Jul 19.
3
Can we use old NAFLD data under the new MASLD definition?在新的代谢相关脂肪性肝病（MASLD）定义下，我们能否使用旧的非酒精性脂肪性肝病（NAFLD）数据？
J Hepatol. 2024 Feb;80(2):e54-e56. doi: 10.1016/j.jhep.2023.07.021. Epub 2023 Aug 2.
4
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.多学会专家组关于新的脂肪肝疾病命名的德尔菲共识声明。
J Hepatol. 2023 Dec;79(6):1542-1556. doi: 10.1016/j.jhep.2023.06.003. Epub 2023 Jun 24.
5
Analysis of Changes in Weight, Waist Circumference, or Both, and All-Cause Mortality in Chinese Adults.中国成年人的体重、腰围或两者的变化与全因死亡率的分析。
JAMA Netw Open. 2022 Aug 1;5(8):e2225876. doi: 10.1001/jamanetworkopen.2022.25876.
6
Association of genetic variations with NAFLD in lean individuals.瘦人非酒精性脂肪性肝病相关的遗传变异。
Liver Int. 2022 Jan;42(1):149-160. doi: 10.1111/liv.15078. Epub 2021 Oct 12.
7
Non-alcoholic fatty liver disease.非酒精性脂肪性肝病。
Lancet. 2021 Jun 5;397(10290):2212-2224. doi: 10.1016/S0140-6736(20)32511-3. Epub 2021 Apr 21.
8
Phase Angle From Bioelectrical Impedance for the Assessment of Sarcopenia in Cirrhosis With or Without Ascites.基于生物电阻抗的相位角评估肝硬化伴或不伴腹水患者的肌肉减少症。
Clin Gastroenterol Hepatol. 2021 Sep;19(9):1941-1949.e2. doi: 10.1016/j.cgh.2020.08.066. Epub 2020 Sep 2.
9
Imaging spectrum of abnormal subcutaneous and visceral fat distribution.皮下和内脏脂肪分布异常的影像学表现谱
Insights Imaging. 2020 Feb 13;11(1):24. doi: 10.1186/s13244-019-0833-4.
10
New trends on obesity and NAFLD in Asia.亚洲肥胖和非酒精性脂肪性肝病的新趋势。
J Hepatol. 2017 Oct;67(4):862-873. doi: 10.1016/j.jhep.2017.06.003. Epub 2017 Jun 19.
Zotero 插件